每經AI快訊，2022年(nian)(nian)(nian)8月(yue)8日(ri)，深(shen)交(jiao)所向深(shen)圳翰宇藥(yao)業（SZ 300199，收盤價：12.91元）股份有限公(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)發(fa)(fa)(fa)出監管函(han)：2022年(nian)(nian)(nian)3月(yue)16日(ri)，你(ni)(ni)公(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)在(zai)本(ben)所互(hu)動易(yi)平臺回復投資者問詢(xun)時(shi)表(biao)示(shi)，“公(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)開發(fa)(fa)(fa)的(de)(de)(de)多(duo)肽鼻噴(pen)(pen)藥(yao)物與輝瑞最(zui)近(jin)上(shang)(shang)市(shi)的(de)(de)(de)口服(fu)片劑(ji)作用機(ji)理不同，目(mu)前(qian)尚處于快速開發(fa)(fa)(fa)階段(duan)，從體外藥(yao)效公(gong)(gong)(gong)(gong)(gong)(gong)開數據看，公(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)開發(fa)(fa)(fa)的(de)(de)(de)多(duo)肽鼻噴(pen)(pen)劑(ji)對(dui)(dui)病毒的(de)(de)(de)抑制活(huo)性(xing)比其高60倍(bei)左右。”2022年(nian)(nian)(nian)4月(yue)13日(ri)，你(ni)(ni)公(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)披露的(de)(de)(de)《關于對(dui)(dui)深(shen)圳證券(quan)交(jiao)易(yi)所問詢(xun)函(han)回復的(de)(de)(de)公(gong)(gong)(gong)(gong)(gong)(gong)告》顯(xian)示(shi)，你(ni)(ni)公(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)“采用針(zhen)對(dui)(dui)當(dang)前(qian)主要流行變異株(zhu)Omicron的(de)(de)(de)數據進(jin)行比較(jiao)”，且你(ni)(ni)公(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)“在(zai)深(shen)圳三院進(jin)行試驗(yan)時(shi)，采用了(le)DMSO溶解實(shi)驗(yan)室(shi)原料藥(yao)，并未(wei)(wei)進(jin)行培養條(tiao)件摸索，未(wei)(wei)能(neng)通(tong)過CPE觀察得到EC50”。你(ni)(ni)公(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)在(zai)互(hu)動易(yi)回復多(duo)肽鼻噴(pen)(pen)藥(yao)物相(xiang)關內容時(shi)，未(wei)(wei)明確說明“抑制活(huo)性(xing)比輝瑞相(xiang)關藥(yao)物高60倍(bei)左右”系針(zhen)對(dui)(dui)何種病毒，且未(wei)(wei)提示(shi)你(ni)(ni)公(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)在(zai)深(shen)圳三院試驗(yan)的(de)(de)(de)相(xiang)關情況及結果，你(ni)(ni)公(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)在(zai)互(hu)動易(yi)平臺發(fa)(fa)(fa)布的(de)(de)(de)信息不謹慎、不完整。你(ni)(ni)公(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)的(de)(de)(de)相(xiang)關行為違反了(le)本(ben)所《上(shang)(shang)市(shi)公(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)自(zi)律監管指引第(di)2號——創業板(ban)上(shang)(shang)市(shi)公(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)規范運作》第(di)8.5.2條(tiao)、第(di)8.5.3條(tiao)的(de)(de)(de)規定。請你(ni)(ni)公(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)董(dong)事(shi)會(hui)充分重視(shi)相(xiang)關問題(ti)，吸取教訓，及時(shi)整改，杜絕相(xiang)關問題(ti)的(de)(de)(de)再次(ci)發(fa)(fa)(fa)生。

2021年1至12月份，翰宇藥(yao)業(ye)的營業(ye)收入構成為(wei)：醫(yi)藥(yao)制造業(ye)占比100.0%。

截至發(fa)稿，翰宇藥業(ye)市值(zhi)為118億元。

道達號（daoda1997）“個股趨勢”提醒：
1. 翰宇藥業近30日內北向資金持股量未發生變化；
2. 近30日內無機構對翰宇藥業進行調研。
更多個股趨(qu)勢信(xin)息(xi)，請搜(sou)索(suo)微信(xin)公眾號(hao)“道達號(hao)”，回復“查詢(xun)”，領取免費查詢(xun)權(quan)限！

每經頭條（nbdtoutiao）——

(記者 賈運可)

免責聲(sheng)明：本文內(nei)容與數(shu)據僅供參考，不構成投資(zi)建議，使(shi)用前請核(he)實。據此操作，風險自擔。